Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Cynosure (CYNO) Share Price
News headlines about Cynosure (NASDAQ:CYNO) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cynosure earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.3331748526979 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s analysis:
- FMI Predicts Dermatology Devices Market Is Expected to Reach US$ 5,307.6 Mn by 2026 (sbwire.com)
- Anti-aging Market to witness comprehensive growth and insights shared in detailed report 2025 – Medgadget (blog) (medgadget.com)
- Aesthetics Combination Therapy Market : Scar Removal to Grow at 8.5% CAGR by 2024 – The Global Health News (press release) (blog) (theglobalhealthnews.com)
- Global Surgical Lasers Market Key Companies: Lumenis, Cynosure,Abbott Laboratories, Boston Scientific Corporation … – TopExaminer (press release) (topexaminer.com)
- Scar Treatment Market Will Grow Rapidly Based On Rising Number Of Road Accidents Till 2025: Grand View Research, Inc. (medgadget.com)
Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.
Receive News & Stock Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related stocks with our FREE daily email newsletter.